Early Phase 1 Sleep Disorders Trial, Recruiting NCT06281756 Sponsor: Milton S. Hershey Medical Center Condition: Sleep Disorders
Back to Sleep Disorders

Early Phase 1 Sleep Disorders Trial, Recruiting

NCT06281756
Recruiting Early Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 or older
  • People who can read and communicate effectively in English (at US sites), or in English or French (at the Canadian site)
  • People who meet the clinical criteria for chronic insomnia
  • People with a Body Mass Index (BMI) of 18.5 or higher

Who may not be able to join:

  • People under the age of 18
  • People who are not able to read and communicate effectively in English (at US sites), or in English or French (at the Canadian site)
  • People who are unwilling to share an email address or cell phone number to receive survey links
  • People who have ever been diagnosed with a psychotic disorder or bipolar disorder
  • People who have a history of severe sleep apnea, or a certain level of breathing interruptions during sleep (AHI of 15 or higher), that has not been treated with an airway pressure device, an oral device, an implanted device, surgery, or weight loss
  • People who have started or changed a treatment for sleep apnea in the past three months
  • People who do not meet the clinical criteria for chronic insomnia
  • People who meet the criteria for narcolepsy or a disorder involving excessive daytime sleepiness
  • People who meet the criteria for a circadian rhythm disorder, including those who regularly work night shifts
  • People with unstable medical conditions that could make participation unsafe or not practical
  • People who have had a fall resulting in hospitalisation, significant injury, or a broken bone in the past 12 months
  • People who have had two or more hospitalisations or emergency room visits for ongoing health conditions in the past 12 months
  • People currently receiving chemotherapy or radiation therapy for cancer
  • People who have ever been diagnosed with or treated for chronic kidney failure, liver insufficiency, or chronic heart failure
  • People who are unwilling to avoid other insomnia treatments beyond what is offered in this study
  • People with a BMI below 18.5
  • People who have experienced substance abuse or dependence in the past 12 months
  • People who are currently taking prescription or over-the-counter sleep medications more than twice per week
  • People currently using systemic corticosteroid medications or opiate medications
  • People who are currently pregnant or breastfeeding, plan to become pregnant, or are unwilling to use birth control for the duration of the study
  • People currently taking medications that are not compatible with the drug trazodone (confirm with trial site)
  • People found to have sleep apnea or periodic leg movement disorder based on a sleep study
  • People with high blood pressure readings at or above certain levels (seated systolic pressure above 180 or diastolic pressure above 110 mmHg) (confirm with trial site)
  • People with a specific heart rhythm measurement (corrected QT interval) of 500 ms or higher on an ECG (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.

Contact this trial

Principal Investigator: Alexandros Vgontzas, MD, Professor, Psychiatry

Phone: 717-531-4123

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Early Phase 1
Sponsor
Milton S. Hershey Medical Center
Registry
ClinicalTrials.gov
Start date
20 March 2024
Est. completion
30 November 2027

Where this trial is recruiting

🇨🇦 Canada 🇺🇸 United States

Primary endpoints

Remission of insomnia symptoms following Cognitive Behavioral Therapy for Insomnia (CBT-I); Remission of insomnia symptoms following trazodone/placebo Randomized Controlled Trial (RCT); Remission of insomnia symptoms 6 months following completion of CBT-I Or RCT Treatment

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov